IDH2 and central nervous system cancer: However, IDH mutation leads to the consumption of α-KG and NADPH to produce an oncometabolite, D-2-hydroxyglutarate (D2HG), directly involved in G-CIMP phenotype inducing and aberrant DNA methylation in gliomas (40, 41).